alpha-aminopyridine has been researched along with Neoplasms in 104 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (2.88) | 18.7374 |
| 1990's | 2 (1.92) | 18.2507 |
| 2000's | 2 (1.92) | 29.6817 |
| 2010's | 71 (68.27) | 24.3611 |
| 2020's | 26 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, Y; Fukami, TA; Hasegawa, K; Kim, SJ; Miura, T; Na, YJ; Ono, N; Shimma, N; Shindo, H; Shiratori, Y; Suda, A; Tsukuda, T; Yoon, DO | 1 |
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| Deng, M; Gao, Y; Gong, Y; Jia, Y; Ling, Y; Liu, X; Yang, C; Yang, Y; Zhou, Y | 1 |
| Hase, S; Ikenaka, T; Kato, I; Kondo, A; Suzuki, J | 1 |
| Bridge, JA; Ferguson, K; Pressey, JG; Sadaf, A; Sorger, JI; Sumegi, J; Szabo, S | 1 |
| Bailly, C | 1 |
| Greenberg, J; Healey, JH; Hsu, C; LaCreta, F; Lasseter, KC; Marbury, TC; Stacchiotti, S; Tap, WD; Xu, LA; Zahir, H | 1 |
| Chen, T; Hou, L; Huang, Y; Jiang, T; Ma, Z; Shi, Z; Wang, S; Yang, F | 1 |
| Ando, K; Choi, I; Gillings, M; Hidaka, M; Ishida, T; Lee, GT; Onogi, H; Takamatsu, Y; Tobinai, K; Yoshida, S; Yoshimitsu, M | 1 |
| Bajrami, B; Brousseau, M; Caliman, A; Campbell, AJ; Ebert, BL; Fischer, ES; Garvie, CW; Giacomelli, AO; Gibson, CJ; Guo, Q; Iqbal, S; Jiang, W; Jin, C; Kahn, J; Lintner, R; Miller, PG; Moroco, JA; Piccioni, F; Qian, Y; Raffier, C; Ranaghan, M; Root, DE; Sathappa, M; Shaw, S; Sperling, AS; Vernier, C; Yang, X | 1 |
| Chang, L; Fu, S; Gao, T; Liang, S; Liu, X; Liu, Y; Mu, W; Sang, X; Shen, Y; Yang, H; Zhang, N; Zhang, Z | 1 |
| Guo, Y; Guo, Z; Han, Q; Hu, J; Hu, X; Jin, S; Song, D; Wang, X; Yang, T; Zhao, J | 1 |
| Chu, T; Li, B; Li, S; Lu, Z; Nie, G; Qi, F; Song, Z; Sukumar, S; Wang, M; Wei, J; Wu, S; Xu, J; Zhang, C; Zhu, F | 1 |
| Adler, FR; Bild, AH; Chen, J; Emond, R; Griffiths, JI; Grolmusz, VK; Medina, EF; Nath, A; Sousa, RS; Synold, T | 1 |
| de Leng, WWJ; de Vos, FYFL; de Wit, GF; Espinoza, D; Gelderblom, H; Geurts, BS; Hoes, LR; Jansen, AML; Lee, CK; Leek, LVM; Lin, FP; Looze, EJ; Roepman, P; Sebastian, L; Simes, RJ; Sjoquist, KM; Thavaneswaran, S; Thomas, DM; van Berge Henegouwen, JM; van der Noort, V; van der Wijngaart, H; van Herpen, CML; Verheul, HMW; Voest, EE; Zeverijn, LJ | 1 |
| Becker, KP; Burris, HA; Chowdhary, SA; Eakle, JF; Hainsworth, JD; Langdon, RM; Mekhail, T; Padula, GDA; Scarberry, M; Shaifer, CA; Shastry, M; Shih, K; West-Osterfield, K; Wright, D; Yost, KJ | 1 |
| Ikonomov, OC; Sbrissa, D; Shisheva, A | 1 |
| Alfieri, R; Bonelli, M; Fumarola, C; La Monica, S | 1 |
| Cho, HW; Ju, HY; Kim, NKD; Koo, HH; Lee, JW; Lee, SH; Ma, Y; Park, WY; Sung, KW; Yoo, KH | 1 |
| Bjelic, S; Friedman, R; Georgoulia, PS | 1 |
| Akce, M; Alese, OB; Bilen, MA; Carthon, B; Chen, Z; Collins, H; El-Rayes, BF; Harris, WB; Harvey, RD; Khuri, FR; Kudchagkar, RR; Lawson, DH; Lewis, C; Lonial, S; Owonikoko, TK; Ramalingam, SS; Shaib, WL; Sica, GL; Steuer, CE; Wu, C; Zhang, C | 1 |
| André, T; Bay, JO; Bouleuc, C; Hervé, L; Magné, N; Penel, N; Rodrigues, M; Sabatier, R; Thiery-Vuillemin, A; Wislez, M | 1 |
| Bui, NL; Chong, QY; Goh, BC; Kok, ZH; Lobie, PE; Sethi, G; Wang, L; Wong, AL; Xiang, X; Yong, WP | 1 |
| Bongers, BJ; Dilweg, MA; Gutiérrez-de-Terán, H; Habben Jansen, MCC; Heitman, LH; IJzerman, AP; Jespers, W; Stangenberger, CM; van Westen, GJP; Wang, X | 1 |
| Belsito, DV; Bergfeld, WF; Burnett, CL; Gill, LJ; Heldreth, B; Hill, RA; Klaassen, CD; Liebler, DC; Marks, JG; Shank, RC; Slaga, TJ; Snyder, PW | 1 |
| Bang, YJ; Bendell, J; Carlsen, M; Chow, KH; Chung, HC; de Miguel, MJ; Gandhi, L; Italiano, A; Lin, CC; Patnaik, A; Schmidt, S; Su, WC; Szpurka, AM; Vangerow, B; Xu, X; Yap, TA; Yu, D; Zhao, Y | 1 |
| Abida, W; Brownstein, S; Drilon, A; Gounder, MM; Groover, A; Harding, JJ; Hyman, DM; Janku, F; Lacouture, ME; Lezcano, C; Li, BT; Liu, D; Offin, M; Sullivan, RJ; Torrisi, JM; Varterasian, M; Welsch, D; Wu, J | 1 |
| Chapman, SC; Han, R; Hu, X; Ji, D; Li, W; Shen, W; Sykes, AK; Tao, H; Wang, N; Yang, N; Zhang, J; Zhang, W | 1 |
| Anderson, B; Azaro, A; Benhadji, KA; Cassier, PA; Italiano, A; Massard, C; Merchan, J; Oakley, G; Pant, S; Tap, WD; Yu, D; Yuen, E | 1 |
| Cao, J; Che, J; Chen, B; Cheng, G; Dong, X; He, Q; Hu, Y; Jin, Z; Xie, J; Yan, F; Yang, B; You, J; Zhu, H | 1 |
| Bardia, A; Sellers, WR; Tripathy, D | 2 |
| Chan, EM; Cronier, DM; Kulanthaivel, P; Sykes, AK; Tate, SC; Turner, PK | 1 |
| Chick, JM; Dyson, NJ; Gao, H; Gao, X; Geng, Y; Gerdemann, U; Gygi, SP; Haining, WN; Keibler, MA; Nicolay, BN; Polyak, K; Ren, H; Roberts, TM; Sicinska, E; Sicinski, P; Suski, JM; Wang, H; Williams, JA; Yang, G | 1 |
| Beaufils, F; Bohnacker, T; Borsari, C; Cmiljanovic, N; Cmiljanovic, V; Fabbro, D; Giese, B; Hebeisen, P; Hillmann, P; Jackson, E; Marone, R; Melone, A; Mestan, J; Rageot, D; Sele, A; Williams, RL; Wymann, MP; Zhang, X; Zvelebil, M | 1 |
| Chen, B; Kraus, D; Palasuberniam, P | 1 |
| Sorscher, S | 1 |
| Alessi, DR; Arkin, MR; Bainbridge, TW; Beresini, MH; Blackwood, E; Blake, RA; Brasher, B; Chang, MT; Clark, KR; Cohen, F; Di Lello, P; Drummond, J; Ernst, JA; Forrest, WF; Gnad, F; Hearn, BR; Heideker, J; Jaishankar, P; Kategaya, L; Kleinheinz, T; Klijn, C; Kwok, MCM; Lin, E; Ma, TP; Martin, SE; Maurer, T; McCleland, M; Murray, J; Ndubaku, C; Pastor, R; Peale, F; Prakash, S; Renslo, AR; Ritorto, MS; Rougé, L; Schwerdtfeger, C; Stiffler, Z; Tang, Y; Trost, M; Tsui, V; Upton, JP; Wang, X; Wertz, IE; Yu, K | 1 |
| Doi, T; Hewes, B; Ishikawa, N; Kakizume, T; Tajima, T; Yamada, Y | 1 |
| Baquero, C; Beckmann, RP; Bi, C; Boehnke, K; Bray, SM; Buchanan, SG; Caldwell, CW; Chio, LC; Chu, S; De Dios, A; Dempsey, J; Dowless, M; Du, J; Gong, X; Iversen, PW; Lallena, MJ; Litchfield, LM; Marugán, C; Merzoug, FF; Mur, C; Qian, HR; Reinhard, C; Stewart, TR; Torres, R; Webster, Y; Wong, SS; Wulur, IH; Ye, XS; Yu, C; Zeng, Y | 1 |
| Benes, CH; Damon, LJ; Dardaei, L; Dastur, A; Dicecca, R; Engelman, JA; Farago, AF; Fintelmann, FJ; Friboulet, L; Gainor, JF; Greenberg, M; Held, MA; Kattermann, KE; Kodack, DP; Lee, D; Niederst, MJ; Parks, M; Piotrowska, Z; Riley, AK; Rizzo, C; Sequist, LV; Shaw, AT; von Flotow, F | 1 |
| Ansell, P; Donawho, C; Falchook, G; Hoening, E; Hong, D; Janisch, L; Karovic, S; Kurzrock, R; Lian, GK; Maitland, ML; McKee, M; Munasinghe, W; Nguyen, L; Palma, J; Piha-Paul, S; Ratain, MJ; Wong, S | 1 |
| Chi, W; Ferber, G; Jackson, J; Janku, F; Li, BT; Mendzelevski, B; Sager, PT; Sullivan, RJ; Welsch, D; Weng, O | 1 |
| Grant, FM; Gyori, D; Hawkins, PT; Lim, EL; Okkenhaug, K; Roychoudhuri, R; Shuttleworth, SJ; Spensberger, D; Stephens, LR | 1 |
| Chen, J; Gomez, D; Li, Y; Liu, L; Palmisano, M; Tong, Z; Zhou, S | 1 |
| Acker, M; Bagdanoff, JT; Chan, H; Chen, YN; Chen, Z; Firestone, B; Fodor, M; Fortanet, J; Hao, H; Hentemann, M; Kato, M; Koenig, R; LaBonte, LR; LaMarche, MJ; Liu, C; Liu, G; Liu, S; McNeill, E; Mohseni, M; Sarver, P; Sendzik, M; Spence, S; Stams, T; Tamez, V; Tichkule, R; Towler, C; Wang, H; Wang, P; Williams, SL; Yu, B | 1 |
| Burgess, K; Zhao, B | 1 |
| Chen, TW; Cheng, AL; Chiu, LL; Hsu, CH; Ishizuka, T; Lee, JH; Lin, CC; Oguma, T; Sasaki, SI; Sugihara, M; Tajima, N; Yang, JC; Yen, YH | 1 |
| Arkenau, HT; Auger, KR; Blagden, SP; Fleming, RA; Gazzah, A; Greystoke, A; Mak, G; Mazumdar, J; Nebot, N; Plummer, R; Rizzuto, I; Rogan, D; Soria, JC; Tolson, J; Yan, L; Zhang, J | 1 |
| Adewole, KE; Ishola, AA | 1 |
| Alarcon, S; Collins, J; Doroshow, JH; Kinders, RJ; Kummar, S; Lee, MJ; Park, SR; Pfister, T; Piekarz, R; Speranza, G; Steinberg, SM; Trepel, JB; Wang, L; Wright, JJ | 1 |
| Fox, JL | 1 |
| Babinski, DJ; Best, AM; Brekken, RA; Bruick, R; Chang, J; Dellinger, M; Easmon, J; Frantz, DE; Kumar, S; Martinez, ED; Peña-Llopis, S; Quinn, AM; Ruiz, J; Simeonov, A; Varghese, D; Wang, L; Xu, J | 1 |
| Chen, SS; Dong, M; Feng, FY; Hu, XS; Shi, YK; Xing, PY | 1 |
| Nakagawa, T; Yano, S | 1 |
| Brandt, M; Cui, G; Darcy, MG; Diaz, E; Faitg, TH; Federowicz, K; Gilmartin, AG; Groy, A; Heerding, DA; Jaworski, JP; Jones, A; Kirkpatrick, RB; Kumar, R; Martens, S; McNulty, DE; Minthorn, E; Nevins, N; Peng, X; Pietrak, B; Richter, M; Schaber, M; Schwartz, B; Seefeld, MA; Sinnamon, RH; Yang, J; Zhang, H; Zhang, SY | 1 |
| Ashton, TM; Fokas, E; Hussien, K; Kannan, P; Kelly, CJ; Muschel, RJ; Pearson, N; Shipley, RJ; Stratford, M | 1 |
| Bendell, JC; Braña, I; De Jonge, MJ; Di Tomaso, E; Eskens, F; Homji, N; Massacesi, C; Mills, D; Rodon, J; Sarr, C; Siu, LL; Trandafir, L | 1 |
| Abe, T; Adachi, Y; Funahashi, Y; Kato, Y; Kawano, S; Matsui, J; Matsushima, T; Nakagawa, T; Nakazawa, Y; Semba, T; Tsuruoka, A; Yokoi, A | 1 |
| Ajamie, RT; Cai, S; Chan, EM; Cronier, D; de Dios, A; Del Prado, M; Flack, RS; Gelbert, LM; Iversen, P; Kreklau, E; Lallena, MJ; Lin, X; Neubauer, BL; Sanchez-Martinez, C; Torres, R; Wishart, GN; Young, J | 1 |
| Blanco-Codesido, M; Brunetto, AT; Daniele, G; de Las Heras, B; Dean, EJ; Greystoke, AP; Krebs, MG; Kuznetsov, G; Lee, L; Molife, LR; Myint, KT; Ranson, MR; Wood, K | 1 |
| Bedard, PL; Britten, CD; Carter, K; Csonka, D; Demanse, D; Janku, F; Le, N; Nauwelaerts, H; Paz-Ares, L; Pérez-García, J; Peters, M; Sessa, C; Stathis, A; Tabernero, J; Van Cutsem, E; Vansteenkiste, J; Wainberg, ZA; Zubel, A | 1 |
| Huang, Q; Liu, S; Pan, H; Xia, J; Yuan, Y | 1 |
| Bialer, P; Carvajal, RD; Fury, MG; Gerecitano, JF; Ho, AL; Hyman, DM; Iasonos, A; Katabi, N; Konner, J; Lacouture, ME; Monson, KR; Snyder, AE; Spriggs, DR; Stasi, MA; Teitcher, JB; Voss, MH; Winkelmann, JL | 1 |
| Affolter, T; Bezwada, D; Deng, S; Dinh, DM; Engstrom, LD; Fantin, VR; Frias, RL; Friboulet, L; Gainor, JF; Gukasyan, H; Hu, W; Jain, RK; Johnson, TW; Katayama, R; Kodack, DP; Lam, H; Lam, JL; Lappin, PB; Lee, N; Li, Q; Lifshits, E; Mahmood, S; Patel, B; Shaw, AT; Smeal, T; Tang, RW; Timofeevski, S; Tsaparikos, K; Wang, H; Wang, J; West, M; Yamazaki, S; Zou, HY | 1 |
| Dou, G; Gan, H; Gu, R; Li, J; Liu, T; Meng, Z; Wu, Z; Zheng, Y; Zhu, X | 1 |
| Carlson, C; Ivanova, A; McRee, AJ; O'Neil, BH; Sanoff, HK | 1 |
| Esfandiari, A; Hawthorne, TA; Lunec, J; Nakjang, S | 1 |
| Hamilton, E; Infante, JR | 1 |
| Finn, RS; O'Leary, B; Turner, NC | 1 |
| Dobbelstein, M; Li, Y; Najafova, Z; Radovanovic, M; Sriraman, A; Wienken, M | 1 |
| Beckmann, RP; Beeram, M; Chan, EM; Cronier, DM; Flaherty, KT; Frenzel, M; Fulford, AD; Gandhi, L; Goldman, JW; Hilton, JF; Kulanthaivel, P; Li, LQ; Martinez, R; Nasir, A; Nguyen, TS; Papadopoulos, KP; Patnaik, A; Rasco, DW; Rosen, LS; Schade, AE; Shapiro, GI; Tolaney, SM; Tolcher, AW; Wen, PY | 1 |
| Asou, H; Chan, EM; Fujiwara, Y; Iwasa, S; Kitano, S; Kondo, S; Mori, J; Ogasawara, K; Shimomura, A; Tamura, K; Tanabe, Y; Turner, PK; Yamamoto, N | 1 |
| Lim, JS; Turner, NC; Yap, TA | 1 |
| Gray, JW | 1 |
| Devaraj, VC; Mullangi, R; Srinivas, NR; Suresh, PS | 1 |
| Cassier, PA; Chakraborty, A; Chugh, R; Crystal, AS; Dobson, JR; Gerecitano, JF; Infante, JR; Matano, A; Parasuraman, S; Ribrag, V; Shapiro, GI; Witteveen, PO | 1 |
| Gao, S; Li, X; Xu, W; Zang, J; Zhang, Y | 1 |
| Arkenau, HT; Auger, KR; Bahleda, R; Blagden, SP; Brown, J; Dean, E; Evans, TR; Fleming, RA; Gan, HK; Gibson, D; Hollebecque, A; Lemech, C; Mazumdar, J; Millward, M; Murray, S; Nebot, N; Peddareddigari, V; Plummer, R; Ranson, M; Singh, R; Soria, JC; Swartz, L; Zalcman, G | 1 |
| Dong, T; Duval, V; Hazell, K; Trandafir, L; Wu, YL; Xu, B; Zhang, LI | 1 |
| Mullard, A | 1 |
| Bekaii-Saab, T; Bloomston, M; Che, Z; Elnaggar, O; Farren, MR; Farris, AB; Guttridge, DC; Lesinski, GB; Mace, TA; Maskarinec, JM; Rajasekera, P; Talbert, EE; Timmers, CD; Yang, J; Young, GS | 1 |
| Anderson, N; Andrade, K; Fornetti, J; McHale, M; Miller, SC; Randall, RL; Waltz, SE; Welm, AL; Zhao, L | 1 |
| Cao, Y; Finlay, JL; Gu, N; Li, C; Lin, J; Pierson, CR; Tian, J; Wu, R; Xiao, H; Xu, R; Yang, F | 1 |
| Abbadessa, G; Eathiraj, S; Hall, T; Schwartz, B; Wick, MJ; Yu, Y | 1 |
| Behrmann, CA; Ennis, KN; Feng, X; Jiang, TT; Kofuji, S; Liu, H; Niu, L; Plas, DR; Sarma, P; Sasaki, AT; Stratton, Y; Thomas, HE; Yoon, SO | 1 |
| Abida, W; Bialer, P; Drilon, A; Erinjeri, JP; Fury, MG; Gerecitano, JF; Gounder, M; Harding, JJ; Ho, AL; Hyman, DM; Iasonos, A; Iyer, G; Jhaveri, K; Katabi, N; Lacouture, ME; Li, BT; Makker, V; Monson, KR; Razavi, P; Smyth, LM; Teitcher, JB; Voss, MH | 1 |
| Han, DC; Han, YM; Kim, JA; Kwon, BM; Lee, JS; Lee, YJ; Shin, DS; Shin, KD; Yoon, YJ | 1 |
| Chen, L; Guo, L; He, Y; Lai, W; Li, J; Lu, X; Ning, Z; Pan, D; Peng, Z; Song, S; Wong, JC; Xie, C; Zhang, C; Zhang, N; Zhang, W; Zhang, X; Zhang, Z | 1 |
| Appleton, BA; Blank, J; Buck, E; Degenkolbe, E; Drueckes, P; Furet, P; Haasen, D; Hofmann, F; Jones, MD; McCarthy, C; Monahan, JE; Ruddy, DA; Schoepfer, J; Sellers, WR; Tiedt, R; Wagner, S; Wartmann, M | 1 |
| Fiedler, W; Schultze, A | 1 |
| Dong, M; Du, X; Li, ZB; Lu, XP; Newman, MJ; Ning, ZQ; Pan, DS; Shan, S; Wang, XH; Zhang, J | 1 |
| Clarke, PA; Workman, P | 1 |
| Baselga, J; Bendell, JC; Birle, D; Burris, HA; De Buck, SS; de Jonge, M; Demanse, D; Goldbrunner, M; Peters, M; Rodon, J; Ru, QC; Verweij, J | 1 |
| Brachmann, S; Burger, M; Chène, P; De Pover, A; Dorsch, M; Fabbro, D; Fritsch, C; García-Echeverría, C; Guthy, D; Hofmann, F; Huang, A; Knapp, M; Maira, SM; Martiny-Baron, G; Menezes, D; Nagel, T; Pecchi, S; Schlegel, R; Schnell, C; Sellers, WR; Shoemaker, K; Sterker, D; Voliva, CF; Wiesmann, M; Wilson, CJ | 1 |
| Cao, HX; Dong, M; Dou, GF; Feng, FY; Lu, XP; Meng, ZY; Ning, ZQ; Shi, YK; Xing, PY; Xu, JL | 1 |
| Calses, P; Huang, JW; Kemp, CJ; Taniguchi, T; Wang, Y | 1 |
| Bradbury, P; Jodrell, DI; Talbot, DC; Wall, L | 1 |
| Cho, EH; Chung, SG; Jeong, EJ; Joo, JH; Kang, DW; Kim, YJ; Kwon, HS; Lee, MS; Lee, SH; Park, SK; Song, HS; Yi, EY | 1 |
| Lobisch, M; Lüben, V; Müller, H; Wörz, R | 1 |
| Burchiel, KJ; Russell, LC | 1 |
| Scheef, W | 1 |
| Scheef, W; Wolf-Gruber, D | 1 |
14 review(s) available for alpha-aminopyridine and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
The potential value of amlexanox in the treatment of cancer: Molecular targets and therapeutic perspectives.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Drug Delivery Systems; Humans; Neoplasms; Treatment Outcome | 2022 |
Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Heterocyclic Compounds, 3-Ring; Humans; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Binding; Translational Research, Biomedical | 2019 |
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation.
Topics: Aminopyridines; Animals; Antineoplastic Agents, Immunological; Benzimidazoles; Cell Cycle Checkpoints; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Humans; Immunomodulation; Neoplasms; Piperazines; Purines; Pyridines | 2019 |
[2019 international oncology news: A compendium].
Topics: Aminopyridines; Breast Neoplasms; Clinical Trials as Topic; Digestive System Neoplasms; Female; Genital Neoplasms, Female; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms; Purines | 2020 |
A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; G1 Phase Cell Cycle Checkpoints; Humans; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Treatment Outcome | 2020 |
Safety Assessment of 2-Amino-3-Hydroxypyridine as Used in Cosmetics.
Topics: Aminopyridines; Animals; Consumer Product Safety; Hair Dyes; Humans; Neoplasms; Risk Assessment; Toxicity Tests | 2020 |
Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.
Topics: Aminopyridines; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Humans; Neoplasms; Protein Kinase Inhibitors; Purines; Signal Transduction; Treatment Outcome | 2017 |
[Progress in cancer treatment with histone deacetylase inhibitor].
Topics: Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Depsipeptides; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Indoles; Neoplasms; Panobinostat; Sulfonamides; Vorinostat | 2013 |
Targeting CDK4/6 in patients with cancer.
Topics: Aminopyridines; Antineoplastic Agents; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Drug Therapy, Combination; Humans; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Purines; Pyridines; raf Kinases; Signal Transduction | 2016 |
Treating cancer with selective CDK4/6 inhibitors.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cell Cycle; Clinical Trials as Topic; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Forecasting; Humans; Molecular Targeted Therapy; Neoplasms; Piperazines; Purines; Pyridines | 2016 |
Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine.
Topics: Aminopyridines; Animals; Benzamides; Chromatography, High Pressure Liquid; Depsipeptides; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Neoplasms; Panobinostat; Sulfonamides; Tandem Mass Spectrometry; Vorinostat | 2017 |
Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy.
Topics: Administration, Oral; Aminopyridines; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Evaluation, Preclinical; Histone Deacetylase Inhibitors; Humans; Neoplasms | 2017 |
Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Focal Adhesion Kinase 2; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Hydroxamic Acids; Indoles; Male; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Pancreatic Neoplasms; Prostatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides | 2011 |
32 trial(s) available for alpha-aminopyridine and Neoplasms
| Article | Year |
|---|---|
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
Topics: Aminopyridines; Australia; Breast Neoplasms; Cyclin D; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclins; DNA Helicases; Female; Humans; Neoplasms; Nuclear Proteins; Precision Medicine; Protein Kinase Inhibitors | 2023 |
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Neoplasms; Phosphatidylinositol 3-Kinases; Prognosis; Salvage Therapy; Survival Rate | 2019 |
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Prognosis; Survival Rate; Tissue Distribution | 2020 |
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Benzimidazoles; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Prognosis; Ramucirumab | 2021 |
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Analgesics; Anti-Bacterial Agents; Antineoplastic Agents; Drug Eruptions; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Skin; Steroids; Young Adult | 2021 |
A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers.
Topics: Aged; Aminopyridines; Benzimidazoles; China; Female; Humans; Male; Neoplasm Metastasis; Neoplasms | 2021 |
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Benzimidazoles; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalazines; Pyridines; Quinolones | 2021 |
A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Benzimidazoles; Biological Availability; Body Weight; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Sex Factors; Young Adult | 2018 |
Phase I study of single-agent ribociclib in Japanese patients with advanced solid tumors.
Topics: Adult; Aminopyridines; Disease Progression; Drug Administration Schedule; Female; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Purines; Sample Size; Treatment Outcome | 2018 |
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Treatment Outcome | 2018 |
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies.
Topics: Aged; Aminopyridines; Dose-Response Relationship, Drug; Electrocardiography, Ambulatory; Female; Heart Rate; Humans; Long QT Syndrome; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasms; Protein Kinase Inhibitors; Pyrroles | 2018 |
Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects.
Topics: Adult; Aminopyridines; Antineoplastic Agents; Area Under Curve; Asian People; Healthy Volunteers; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Neoplasms; Triazines; White People; Young Adult | 2018 |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Biomarkers, Tumor; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Non-Randomized Controlled Trials as Topic; Prognosis; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Tissue Distribution; Young Adult | 2020 |
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.
Topics: Aged; Aminopyridines; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Hydroxamic Acids; Male; Mesothelioma; Middle Aged; Neoplasms; Progression-Free Survival; Pyridones; Pyrimidinones | 2019 |
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cohort Studies; Colorectal Neoplasms; Endothelial Cells; Female; Head and Neck Neoplasms; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Morpholines; Neoplasms; Oxazines; Pheochromocytoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Thyroid Neoplasms | 2013 |
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Biomarkers, Tumor; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; PTEN Phosphohydrolase | 2014 |
A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Biomarkers; Drug Monitoring; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Piperazines; Protein Kinase Inhibitors; Treatment Outcome | 2014 |
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Pyridones; Pyrimidinones | 2015 |
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome; Young Adult | 2015 |
Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application.
Topics: Aminopyridines; Benzamides; Chromatography, High Pressure Liquid; Histone Deacetylase Inhibitors; Humans; Limit of Detection; Linear Models; Neoplasms; Reproducibility of Results; Tandem Mass Spectrometry | 2015 |
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Leukopenia; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Organoplatinum Compounds; Phosphoinositide-3 Kinase Inhibitors | 2015 |
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.
Topics: Aminopyridines; Antineoplastic Agents; Asian People; Benzimidazoles; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2016 |
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Bayes Theorem; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dose-Response Relationship, Drug; Female; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Purines; Young Adult | 2016 |
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Biopsy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neurofibromin 2; Protein Kinase Inhibitors | 2016 |
Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; China; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Morpholines; Neoplasms; Phosphoinositide-3 Kinase Inhibitors | 2016 |
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Prognosis; PTEN Phosphohydrolase; Tissue Distribution | 2017 |
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors | 2012 |
Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.
Topics: Adolescent; Adult; Aged; Aminopyridines; Benzamides; Female; Histone Deacetylase Inhibitors; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2012 |
A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Drug Administration Schedule; Female; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Metalloendopeptidases; Middle Aged; Musculoskeletal Diseases; Neoplasms; Treatment Outcome | 2004 |
[Treatment of tumor pain with flupirtine. Results of a double-blind study versus tramadol].
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Analgesics; Female; Humans; Male; Middle Aged; Neoplasms; Pain; Pain Measurement; Prospective Studies; Tramadol | 1994 |
Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain.
Topics: Administration, Oral; Aminopyridines; Analgesics; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Neoplasms; Pain; Palliative Care; Pentazocine; Random Allocation | 1987 |
[Flupirtine in patients with cancer pain].
Topics: Aged; Aminopyridines; Analgesics; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Neoplasms; Pain; Pentazocine; Random Allocation | 1985 |
58 other study(ies) available for alpha-aminopyridine and Neoplasms
| Article | Year |
|---|---|
Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
Topics: Adenosine Triphosphatases; Administration, Oral; Animals; Antineoplastic Agents; Benzopyrans; Computer Simulation; Dose-Response Relationship, Drug; Drug Design; Drug Discovery; Escherichia coli; HSP90 Heat-Shock Proteins; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Neoplasms; Reproducibility of Results; Structure-Activity Relationship; Surface Plasmon Resonance; Triazines; Xenograft Model Antitumor Assays | 2011 |
Design, synthesis and in vitro biological evaluation of 2-aminopyridine derivatives as novel PI3Kδ inhibitors for hematological cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Hematologic Neoplasms; Humans; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors | 2023 |
Assay of urinary free fucose by fluorescence labeling and high-performance liquid chromatography.
Topics: Adult; Aged; Aminopyridines; Chromatography, High Pressure Liquid; Creatinine; Female; Fluorescent Dyes; Fucose; Humans; Male; Middle Aged; Neoplasms | 1992 |
Novel ARHGAP23-FER fusion in a metastatic spindle cell-predominant neoplasm with a myofibroblastic phenotype and a sustained metabolic response to lorlatinib.
Topics: Aminopyridines; Humans; Lactams; Neoplasms; Phenotype; Pyrazoles | 2021 |
Effect of Mild and Moderate Hepatic Impairment (Defined by Child-Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics.
Topics: Aminopyridines; Area Under Curve; Humans; Liver Diseases; Multiple Organ Failure; National Cancer Institute (U.S.); Neoplasms; Pyrroles; United States | 2022 |
Chidamide stacked in magnetic polypyrrole nano-composites counter thermotolerance and metastasis for visualized cancer photothermal therapy.
Topics: Aminopyridines; Animals; Benzamides; Magnetic Resonance Imaging; Mice; Neoplasms; Phototherapy; Photothermal Therapy; Polymers; Pyrroles; Thermotolerance | 2022 |
Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin's lymphoma: phase I safety and efficacy.
Topics: Adult; Aminopyridines; Benzamides; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Japan; Lymphoma, T-Cell, Peripheral; Maximum Tolerated Dose; Neoplasms; Prospective Studies; Pyridines | 2022 |
Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state.
Topics: Allosteric Site; Aminopyridines; Dipeptides; Humans; Mutation; Neoplasms; Protein Conformation; Protein Phosphatase 2C; Serine; Structure-Activity Relationship | 2022 |
Two-Wave Variable Nanotheranostic Agents for Dual-Mode Imaging-Guided Photo-Induced Triple-Therapy for Cancer.
Topics: Aminopyridines; Benzimidazoles; Cathepsin B; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Liposomes; Neoplasms; Theranostic Nanomedicine | 2022 |
Amlexanox-modified platinum(IV) complex triggers apoptotic and autophagic bimodal death of cancer cells.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; bcl-2-Associated X Protein; Cell Line, Tumor; Cisplatin; Cytochromes c; DNA; Humans; Microtubule-Associated Proteins; Neoplasms; Platinum; Prodrugs | 2022 |
Nanoparticle-Based Combination Therapy Enhances Fulvestrant Efficacy and Overcomes Tumor Resistance in ER-Positive Breast Cancer.
Topics: Aminopyridines; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Fulvestrant; Mice; Neoplasms; Receptors, Estrogen; Swine | 2023 |
Cell facilitation promotes growth and survival under drug pressure in breast cancer.
Topics: Aminopyridines; Estradiol; Estrogens; Humans; Neoplasms | 2023 |
Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
Topics: Adolescent; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biomarkers, Tumor; Child; Child, Preschool; DNA Copy Number Variations; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exons; Feasibility Studies; Female; High-Throughput Nucleotide Sequencing; Humans; Infant; Lactams; Lactams, Macrocyclic; Male; Molecular Targeted Therapy; Mutation; Neoplasm Recurrence, Local; Neoplasms; Precision Medicine; Pyrazoles; Republic of Korea; Young Adult | 2019 |
Deciphering the molecular mechanism of FLT3 resistance mutations.
Topics: Aminopyridines; Benzothiazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Mutation; Neoplasms; Phenylurea Compounds; Protein Conformation; Protein Kinase Inhibitors; Pyrroles | 2020 |
Characterization of cancer-related somatic mutations in the adenosine A
Topics: Adenosine A2 Receptor Agonists; Adenosine-5'-(N-ethylcarboxamide); Aminopyridines; Computational Biology; Humans; Models, Molecular; Mutation; Neoplasms; Receptor, Adenosine A2B; Saccharomyces cerevisiae | 2020 |
Prognosis Varies by Intrinsic Tumor Subtype in Patients Treated with Ribociclib.
Topics: Aminopyridines; Breast Neoplasms; Female; Humans; Neoplasms; Prognosis; Purines | 2021 |
Discovery of 5,6-Bis(4-methoxy-3-methylphenyl)pyridin-2-amine as a WSB1 Degrader to Inhibit Cancer Cell Metastasis.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Mice, Inbred BALB C; Molecular Structure; Neoplasm Metastasis; Neoplasms; Rats, Sprague-Dawley; Signal Transduction; Structure-Activity Relationship | 2021 |
The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival.
Topics: Aminopyridines; Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin D3; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Glycolysis; Humans; Mice; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphofructokinase-1; Phosphorylation; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Purines; Pyruvate Kinase; Reactive Nitrogen Species; Reactive Oxygen Species; Serine; Xenograft Model Antitumor Assays | 2017 |
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.
Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Brain; Cell Proliferation; Dogs; Humans; Mice; Models, Molecular; Morpholines; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Rats; Rats, Nude; Signal Transduction; TOR Serine-Threonine Kinases | 2017 |
Targeting Phosphatidylinositol 3-Kinase Signaling Pathway for Therapeutic Enhancement of Vascular-Targeted Photodynamic Therapy.
Topics: Aminopyridines; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Endothelial Cells; Humans; Imidazoles; Mice; Morpholines; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Recurrence, Local; Neoplasms; Neovascularization, Pathologic; Oxidative Stress; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Photochemotherapy; Porphyrins; Protein Kinase Inhibitors; Quinolines; Signal Transduction; Thiazoles; Verteporfin; Xenograft Model Antitumor Assays | 2017 |
Mechanism of Action and Clinical Impact of Ribociclib-Letter.
Topics: Aminopyridines; Cyclin-Dependent Kinase 4; Humans; Neoplasms; Purines | 2017 |
Mechanism of Action and Clinical Impact of Ribociclib-Response.
Topics: Aminopyridines; Cyclin-Dependent Kinase 4; Humans; Neoplasms; Purines | 2017 |
USP7 small-molecule inhibitors interfere with ubiquitin binding.
Topics: Aminopyridines; Animals; Binding, Competitive; Cell Line, Tumor; Drug Synergism; Female; Humans; Indazoles; Mice; Mice, SCID; Models, Molecular; Neoplasms; Phenols; Protein Binding; Proto-Oncogene Proteins c-mdm2; Proto-Oncogene Proteins c-pim-1; Pyridines; Substrate Specificity; Tumor Suppressor Protein p53; Ubiquitin; Ubiquitin-Specific Peptidase 7 | 2017 |
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Cell Proliferation; Clinical Trials, Phase I as Topic; Cyclin D; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.
Topics: Acrylamides; Aminopyridines; Anaplastic Lymphoma Kinase; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Feeder Cells; Fluorescent Antibody Technique; Gene Expression; High-Throughput Screening Assays; Humans; Keratin-18; Keratin-8; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Neoplasms; Piperazines; Precision Medicine; Primary Cell Culture; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Tumor Cells, Cultured | 2017 |
Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
Topics: Aminopyridines; Animals; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Diphtheria Toxin; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Forkhead Transcription Factors; Gene Knockout Techniques; Humans; Lymphocyte Depletion; Macrophages; Male; Mice; Mice, Transgenic; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Primary Cell Culture; Purines; Pyrroles; Quinazolinones; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; T-Lymphocytes, Regulatory; Tumor Microenvironment | 2018 |
6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors.
Topics: Administration, Oral; Allosteric Regulation; Allosteric Site; Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Crystallography, X-Ray; Enzyme Inhibitors; Female; Humans; Male; Mice, Inbred C57BL; Molecular Structure; Neoplasms; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyrimidinones; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2019 |
PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer.
Topics: Aminopyridines; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Humans; Kinetics; Neoplasms; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Retinoblastoma Protein | 2019 |
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Artemisinins; Crystallography, X-Ray; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Pyrroles | 2020 |
FDA moves on breakthrough therapies.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Drug Approval; Neoplasms; Quinolones; Terminal Care; United States | 2013 |
A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Epigenesis, Genetic; Histones; Humans; Hydrazones; Inhibitory Concentration 50; Isomerism; Jumonji Domain-Containing Histone Demethylases; Lysine; Methylation; Mice; Neoplasms; Small Molecule Libraries; Survival Analysis; Transcription, Genetic | 2013 |
The current state of molecularly targeted drugs targeting HGF/Met.
Topics: Acrylamides; Afatinib; Aminopyridines; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrrolidinones; Quinazolines; Quinolines; Signal Transduction; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.
Topics: Administration, Oral; Allosteric Regulation; Amino Acid Motifs; Aminopyridines; Animals; Antineoplastic Agents; Catalytic Domain; Cell Line, Tumor; Dipeptides; Disease Models, Animal; Drug Screening Assays, Antitumor; Enzyme Activation; Enzyme Inhibitors; Female; Heterografts; Humans; Mice; Mice, SCID; Models, Biological; Neoplasms; Phosphoprotein Phosphatases; Protein Phosphatase 2C | 2014 |
Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia.
Topics: Aminopyridines; Animals; Cell Hypoxia; Cell Line, Tumor; HCT116 Cells; Humans; Imidazoles; Mice; Morpholines; Neoplasms; Oxygen Consumption; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinolines; Signal Transduction; Spheroids, Cellular; TOR Serine-Threonine Kinases | 2014 |
Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.
Topics: Aminopyridines; Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Hepatocyte Growth Factor; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-met; Quinolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2014 |
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Deoxycytidine; Drug Therapy, Combination; Female; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Mice; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Retinoblastoma Protein; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Bridging continual reassessment method for phase I clinical trials in different ethnic populations.
Topics: Adult; Aminopyridines; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Computer Simulation; Dose-Response Relationship, Drug; Ethnicity; Humans; Maximum Tolerated Dose; Morpholines; Multicenter Studies as Topic; Neoplasms; Pharmacogenetics; Research Design | 2015 |
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Mice; Mutation; Neoplasms; NIH 3T3 Cells; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2015 |
Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Catalysis; Cell Line, Tumor; Cell Survival; Dipeptides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Mutation; Neoplasms; para-Aminobenzoates; Piperazines; Protein Phosphatase 2C; Proteolysis; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Transcription, Genetic; Tumor Suppressor Protein p53; Ubiquitin | 2016 |
Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
Topics: Acetylation; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cellular Senescence; Dipeptides; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Imidazoles; MCF-7 Cells; Neoplasms; Phosphorylation; Piperazines; Protein Phosphatase 2C; Proto-Oncogene Proteins c-mdm2; RNA Interference; Signal Transduction; Time Factors; Transcriptome; Transfection; Tumor Suppressor Protein p53; Up-Regulation | 2016 |
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Models, Animal; Drug Monitoring; Female; Humans; Lung Neoplasms; Male; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Male; Neoplasms; Treatment Outcome | 2016 |
PI3 Kinase Pathway Mutations in Human Cancers.
Topics: Aminopyridines; Class I Phosphatidylinositol 3-Kinases; Humans; Isoquinolines; Molecular Targeted Therapy; Morpholines; Mutation; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Purines; Quinazolinones; Signal Transduction; Tumor Suppressor Protein p53 | 2016 |
Cancer metabolism pipeline breaks new ground.
Topics: Aminopyridines; Antineoplastic Agents; Drug Approval; Drug Discovery; Drug Industry; Humans; Metabolic Networks and Pathways; Neoplasms; Triazines | 2016 |
Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Biomarkers; Body Weight; Cachexia; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Humans; Mice; Mitogen-Activated Protein Kinase Kinases; Morpholines; Muscle, Skeletal; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis.
Topics: Aminopyridines; Animals; Bone and Bones; Estrogens; Female; Humans; Mice; Mice, Transgenic; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Osteoblasts; Osteoclasts; Osteoporosis; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyridones; Receptor Protein-Tyrosine Kinases; Signal Transduction; Treatment Outcome | 2017 |
The Antiproliferative and Colony-suppressive Activities of STAT3 Inhibitors in Human Cancer Cells Is Compromised Under Hypoxic Conditions.
Topics: Aminopyridines; Anthraquinones; Antineoplastic Agents; Cell Growth Processes; Cell Hypoxia; Cell Line, Tumor; Humans; Neoplasms; Neoplastic Stem Cells; STAT3 Transcription Factor; Sulfonamides | 2017 |
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.
Topics: Aminopyridines; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Endometrial Neoplasms; Female; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Fibroblast Growth Factor; Xenograft Model Antitumor Assays | 2017 |
Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Gene Knockdown Techniques; Glioblastoma; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, T-Cell; Mice; Neoplasms; Phosphorylation; PTEN Phosphohydrolase; Pyridones; Receptor Protein-Tyrosine Kinases; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases | 2017 |
KRIBB11 inhibits HSP70 synthesis through inhibition of heat shock factor 1 function by impairing the recruitment of positive transcription elongation factor b to the hsp70 promoter.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Diamines; DNA-Binding Proteins; Drug Delivery Systems; Heat Shock Transcription Factors; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; Humans; Indazoles; Mice; Mice, Nude; Molecular Chaperones; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms; Poly(ADP-ribose) Polymerases; Positive Transcriptional Elongation Factor B; Promoter Regions, Genetic; Transcription Factors | 2011 |
Application of p21 and klf2 reporter gene assays to identify selective histone deacetylase inhibitors for cancer therapy.
Topics: Aminopyridines; Anilides; Antineoplastic Agents; Benzamides; Catalytic Domain; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Genes, Reporter; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Kruppel-Like Transcription Factors; Neoplasms; Promoter Regions, Genetic; Pyrimidines; Structure-Activity Relationship | 2011 |
A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.
Topics: Amino Acid Substitution; Aminopyridines; Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Transformed; Cell Line, Tumor; Crystallography, X-Ray; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Mice; Models, Molecular; Mutagenesis; Mutation, Missense; Neoplasms; Point Mutation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-met; Pyrazoles; Quinolines; Receptors, Growth Factor; Tyrosine | 2011 |
Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
Topics: Acetylation; Aminopyridines; Animals; Benzamides; Cell Growth Processes; Cell Line, Tumor; Cytotoxicity, Immunologic; Female; Gene Expression; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Immunity, Cellular; Isoenzymes; K562 Cells; Killer Cells, Natural; Lymphoma, T-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Xenograft Model Antitumor Assays | 2012 |
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.
Topics: Aminopyridines; Female; Humans; Male; Morpholines; Neoplasms; Phosphoinositide-3 Kinase Inhibitors | 2012 |
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
Topics: Administration, Oral; Aminopyridines; Animals; Biological Availability; Blotting, Western; Cell Line, Tumor; Dose-Response Relationship, Drug; HCT116 Cells; HT29 Cells; Humans; Isoenzymes; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Morpholines; Mutation; Neoplasms; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Rats; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzothiazoles; Cisplatin; DNA Repair; Down-Regulation; Female; HCT116 Cells; HeLa Cells; Humans; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Neoplasms; Nuclear Proteins; Nucleotidyltransferases; Poly(ADP-ribose) Polymerase Inhibitors; Rad51 Recombinase; Random Allocation; Xenograft Model Antitumor Assays | 2012 |
Anti-angiogenic and anti-tumor apoptotic activities of SJ-8002, a new piperazine derivative.
Topics: Aminopyridines; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Biological Assay; Caspase 3; Caspases; Cell Line, Tumor; Cell Movement; Chick Embryo; Collagen; Cytochromes c; Drug Combinations; Laminin; Matrix Metalloproteinase 2; Mice; Neoplasms; Neovascularization, Pathologic; Piperazine; Piperazines; Proteoglycans | 2004 |
Effects of potassium channel-blocking agents on spontaneous discharges from neuromas in rats.
Topics: 4-Aminopyridine; Aminopyridines; Animals; Electric Conductivity; Gallamine Triethiodide; Ion Channels; Neoplasms; Nerve Fibers, Myelinated; Neuroma; Peripheral Nervous System Diseases; Potassium; Rats; Rats, Inbred Strains; Tetraethylammonium; Tetraethylammonium Compounds | 1985 |